India: Biosimilars- An Emerging Trend In Indian Pharma Industry

Last Updated: 11 July 2019
Article by Neha Ramani

India released the draft regulatory guidelines for 'Similar Biologics' at the BIO industry conference in Boston, USA, on 19 June 2012. These guidelines were revised in 2016. Under these guidelines Central Drugs Standard Control Organization (CDSCO) is responsible for laying down standards for the drugs, to ensure that the requirements regarding the manufacturing process and quality are met, providing approvals for clinical trials, granting marketing rights, granting import or export licenses and ensuring pre-market and post-market regulatory requirements for biologics.

The Review Committee on Genetic Manipulation (RCGM) is one of the other two competent authorities involved in the approval process for Biosimilars. It functions under the Department of Biotechnology (DBT), Ministry of Science and Technology. RCGM is responsible for reviewing reports and visiting experimental facilities to ensure that adequate safety measures are taken, regulating import, export, transfer, exchange of genetically engineered materials, providing permissions for conducting pre-clinical toxicity studies and recommending appropriate phase of clinical trials to the Drug Controller General of India (DCGI).

The Genetic Engineering Approval Committee (GEAC), which functions under the Department of Environment Forests and Wildlife is a statutory body to examine and issue clearance for environmental safety. Their function is to review and approve activities involving large scale use of genetically engineered organisms and products, release of genetically engineered organisms and products into the environment including experimental field trials and industrial production.

The aforesaid three bodies put together are responsible for the regulatory framework in India for Biosimilars.

With the revised guidelines for similar biologics in 2016, the government has made the approval process more stringent including giving emphasis to the post market regulatory requirements to protect the public interest. The amendments have also brought many positive changes, such as under the previous guidelines, it was essential that the reference biologic for which biosimilar is to be developed, is approved and marketed in India. After the amendment, the reference biologic may be approved or marketed either in India or any other International Council for Harmonisation countries (i.e., European Union, Japan, United States, Canada, and Switzerland). The amendment also tries to align the regulations with other international agencies such as EMA and WHO.

Case Laws

Roche and Genentech Inc. manufactured a breast cancer drug, Trastuzumab (Herceptin) and imported and marketed it in India. The drug dominated the Indian market until the Indian patent lapsed and Biocon launched a biosimilar CANMAb and Mylan Pharmaceuticals launched Hertraz.

Roche filed a case against the Drug Controller General of India (DCGI), Biocon and Mylan before the Delhi High Court, seeking to restrain the sales of their biosimilars, claiming that the approval of the biosimilars did not meet the standard set-out in the Guidelines for Similar Biologics.

In April 2016, the single bench of the Delhi High Court ruled in favour of Roche and held that marketing approvals granted in favour of CANMAb and Hertraz were not in line with the Guidelines. However, keeping in mind public interest and access to cheaper drugs, the court allowed Biocon and Mylan to continue manufacturing, marketing and advertising their products provided the 'biosimilar tag' was removed and the INN name, Trastuzumab, was not used alone.

In March 2017, a Division Bench at Delhi High Court passed an interim order allowing Biocon and Mylan to market their biosimilars for two additional indications: early breast cancer and metastatic gastric cancer. Prior to the passing of this order, Biocon and Mylan, had permission to market their products for only metastatic breast cancer. Roche filed a Special leave petition (SLP) before the Supreme Court to restrain Biocon and Mylan from marketing the biosimilars for the two additional indications but later voluntarily withdrew the SLP.

The Delhi High Court has remained silent on determination of the legal importance and binding character of the Biosimilar Guidelines, 2012 and the fact that Biocon and Mylan were given approval for their biosimilars even though there was no public record that phase 1 and 2 clinical trials were conducted.

Over the last decade, India has emerged as a thriving biosimilar ecosystem in comparison to other countries due to its large population and need for affordable treatment. Biocon has made a major mark in the development of innovative biologics and biosimilars, not just in India but in all major global markets. It has established strong and strategic partnerships with Mylan and Sandoz, which have given them an advantage in obtaining global regulatory approvals and commercialization. They have successfully received approvals from the United States Food and Drug Administration (USFDA) for two biosimilars: Ogivri, a version of trastuzumab for treatment of breast cancer and Fulphila, a version of pegfilgrastim used to increase the white blood count in cancer patients. With a diverse portfolio and numerous innovative biologics and biosimilars in the pipeline, Biocon has taken a lead and opened the US and global drug market for Indian companies.

There is a definite shift in the trend and focus of the pharmaceutical industry in India and across the globe from development of pharmaceuticals to biopharmaceuticals. Despite the heavy costs, infrastructure for R&D and excess time required in the development of biologics, we have seen revamping of businesses, mergers and expansions to increase operational capabilities, as well as splitting, re-shaping and restructuring R&D by pharma companies to diversify into specialty medicine and biologics. It is an exciting time ahead, with a promise of evolution of biopharmaceuticals and breakthroughs in life-changing and life-saving drugs, like we have never seen before.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
S.S. Rana & Co. Advocates
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
S.S. Rana & Co. Advocates
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions